RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
21 Dec 2023
Historique:
accepted: 18 12 2023
received: 05 09 2023
revised: 21 11 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: aheadofprint

Résumé

Aberrant miRNA expression profiles have been associated with disease progression and clinical outcome in pediatric cancers. However, few studies have analyzed genome-wide dysregulation of miRNAs and mRNAs in pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL). To identify novel prognostic factors, we comprehensively investigated miRNA and mRNA sequencing (miRNA-seq and mRNA-seq) data in poor-outcome pediatric BCP-ALL samples. We analyzed 180 patients, including 43 matched pairs at diagnosis and relapse. Consensus clustering of miRNA expression data revealed a distinct profile characterized by mainly downregulation of miRNAs (referred to as an miR-low cluster; MLC). The MLC profile was not associated with any known genetic subgroups. Intriguingly, patients classified as MLC had significantly shorter event-free survival (median 21 vs 33 months, log-rank P = 3 ×10-5). Furthermore, this poor prognosis was retained even in hyperdiploid ALL. This poor prognostic MLC profiling was confirmed in the validation cohort. Notably, non-MLC profiling at diagnosis often (n= 9/23, Fisher's exact test, P = 0.039) changed into MLC profiling at relapse in the same patient. Integrated analysis of miRNA-seq and mRNA-seq data revealed that the transcriptional profile of MLC was characterized by enrichment of MYC target and oxidative phosphorylation genes, reduced intron retention, and low expression of DICER1. Thus, our miRNA-mRNA integration approach yielded a truly unbiased molecular stratification of pediatric BCP-ALL cases based on a novel prognostic miRNA signature, which may lead to better clinical outcomes.

Identifiants

pubmed: 38127276
pii: 506682
doi: 10.1182/bloodadvances.2023011583
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 American Society of Hematology.

Auteurs

Hirohito Kubota (H)

Kyoto University, Kyoto, Japan.

Hiroo Ueno (H)

Kyoto University, Kyoto, Japan.

Keiji Tasaka (K)

Kyoto University, Kyoto, Japan.

Tomoya Isobe (T)

Wellcome-MRC Cambridge Stem Cell Institute, United Kingdom.

Satoshi Saida (S)

Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Itaru Kato (I)

Kyoto University, Kyoto, Japan.

Katsutsugu Umeda (K)

Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Mitsuteru Hiwatari (M)

Teikyo University, Tokyo, Japan.

Daiichiro Hasegawa (D)

Kobe Children's Hosp., Kobe-Shi, Japan.

Toshihiko Imamura (T)

Kyoto Prefectural University of Medicine, Kyoto, Japan.

Nobuyuki Kakiuchi (N)

Kyoto University, Kyoto, Japan.

Yasuhito Nannya (Y)

The University of Tokyo, Tokyo, Japan.

Seishi Ogawa (S)

Kyoto University, Kyoto, Japan.

Junko Takita (J)

Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Classifications MeSH